# Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Study · id `cardio:ct-nct05085275` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05085275](<https://clinicaltrials.gov/study/NCT05085275>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05085275

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.

## Technical summary

Registry record NCT05085275. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-30 (actual); primary completion 2024-01-24 (actual). Results posted on 2025-08-29.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 289 participants (enrolled count; ClinicalTrials.gov record NCT05085275, source copy `cardio:ctgov-nct05085275-2025-08-29`, retrieved 2026-10-26)
- Started: 2022-03-30 (actual) (ClinicalTrials.gov record NCT05085275, source copy `cardio:ctgov-nct05085275-2025-08-29`, retrieved 2026-10-26)
- Primary completion: 2024-01-24 (actual) (ClinicalTrials.gov record NCT05085275, source copy `cardio:ctgov-nct05085275-2025-08-29`, retrieved 2026-10-26)
- Completion: 2024-01-24 (actual) (ClinicalTrials.gov record NCT05085275, source copy `cardio:ctgov-nct05085275-2025-08-29`, retrieved 2026-10-26)
- Results first posted: 2025-08-29 (ClinicalTrials.gov record NCT05085275, source copy `cardio:ctgov-nct05085275-2025-08-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05085275, source copy `cardio:ctgov-nct05085275-2025-08-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05085275-2025-08-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
- Acronym: FRONTIER
- Condition: Anemia, Iron Deficiency
- Condition: Hyperphosphatemia
- Condition: Renal Insufficiency, Chronic
- Condition: Renal Anemia
- Condition: Disease Progression
- Condition: Cardiovascular
- Condition: Iron
- Intervention (Drug): Ferric Citrate 1 GM Oral Tablet \[AURYXIA\]
- Intervention (Drug): Placebo
- Lead sponsor: USRC Kidney Research
- Lead sponsor class: NETWORK
- Collaborator: Akebia Therapeutics
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as a collaborator: Akebia Therapeutics (`cardio:org-akebia-therapeutics`)

## Provenance

Content hash: bbf699bdeac42defffcc2bedf26ad0b24d107b96c7b991a9947ced3d479d27b9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
